President Trump announced yesterday he was taking hydroxychloroquine as a preventive measure for coronavirus disease 2019 (COVID-19) despite reported adverse effects and lack of beneficial evidence; Moderna's COVID-19 vaccine shows early promise; CDC finds less than half of infants 5 months or younger are on track for vital vaccinations.
Weeks after the FDA cautioned against the use of hydroxychloroquine for treatment of coronavirus disease 2019 (COVID-19) due to the risk of serious heart problems and other complications, President Trump announced yesterday that he was taking the drug despite testing negative for the virus. Reported by POLITICO, the admission prompted major concern from health experts, as the treatment has been shown in observational studies to have little to no proven benefits for patients with COVID-19. Moreover, few studies have shown a benefit from taking the drug as a prophylactic measure.
According to early data on the first COVID-19 vaccine to be tested in the United States, manufacturer Moderna Inc said its vaccine was safe and produced protective antibodies in a small group of healthy volunteers. Reported by Reuters, findings from the 8 study participants showed that those who received a 100-μg dose and people who received a 25-μg dose had levels of protective antibodies that exceeded those found in the blood of patients who recovered from the virus. Currently, the Moderna vaccine is 1 of more than 100 under development for protection against COVID-19.
Based on a study conducted by the CDC, vaccination rates in May for children younger than 2 years in Michigan dropped to alarmingly low levels, with fewer than half (49.7%) of infants 5 months or younger shown to be on track for vaccinations of diseases such as measles and pertussis. Reported by The New York Times, the risk of infection for these diseases may have been mitigated in the past 2 months from residents following stay-at-home orders, but as states begin to ease restrictions, health experts have become fearful of potential outbreaks.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More